SCHEMBL20505217

SCHEMBL20505217

Cc1c(F)c(F)cc2c1cc(C#N)n2CCNC(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ MAPT P10636 4/20 0.32
▸ MEN1 O00255 4/20 0.32
▸ KMT2A Q03164 4/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HTT P42858 3/20 0.31
▸ MITF O75030 2/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ TP53 P04637 2/20 0.31
▸ POLB P06746 1/20 0.30
▸ THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28479027 0.86 DYRK1A (0.37) —
SCHEMBL20505409 0.82 SMN1; SMN2 (0.32) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL20505723 0.82 SMN1; SMN2 (0.32) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL20505141 0.80 MEN1 (0.32) MEN1KMT2A
SCHEMBL28486489 0.79 GLA (0.35) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL20504946 0.78 PGR (0.35) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL20505071 0.78 MAP3K8 (0.30) —
SCHEMBL20504840 0.77 PGR (0.33) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL20505463 0.77 SMN1; SMN2 (0.34) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL20504996 0.77 PTGDR2 (0.34) SMN1; SMN2MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 — — US disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 — — US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 — — US disclosed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 — — EP disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 — — US disclosed
EP-3377483-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2018-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 SMN1; SMN2 4553/4885MAPT 4570/4885MEN1 2595/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 SMN1; SMN2 4553/4885MAPT 4570/4885MEN1 2595/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 SMN1; SMN2 4553/4885MAPT 4570/4885MEN1 2595/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 SMN1; SMN2 4553/4885MAPT 4570/4885MEN1 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback